2003 AUG 25 - (NewsRx.com & NewsRx.net) -- CryoCath Technologies, Inc., (CYT) announced that it has received the CE Mark for CryoVasc, a catheter for the treatment of chronic cardiac ischemia.
The CE Mark allows the company to sell the product in all countries of the European Union. Cardiac ischemia is the inadequate flow of blood to a region of the heart, often resulting in severe angina (chest pain). CryoVasc is the sixth cardiac product CryoCath has commercialized in Europe. This European approval follows a key U.S. method and device patent issued providing the company with broad coverage for its cardiac ischemia program.
"A major commercial opportunity …
No comments:
Post a Comment